Published in Drug Resist Updat on December 01, 2002
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets (2011) 2.58
Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem (2005) 1.96
Ubiquitin-dependent regulation of TGFbeta signaling in cancer. Neoplasia (2006) 1.14
Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia (2006) 1.14
The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol (2012) 1.01
A functional analysis reveals dependence on the anaphase-promoting complex for prolonged life span in yeast. Genetics (2004) 0.94
The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol (2012) 0.92
Effects of partner proteins on BCA2 RING ligase activity. BMC Cancer (2012) 0.89
Protacs for treatment of cancer. Pediatr Res (2010) 0.83
Contribution of CAF-I to anaphase-promoting-complex-mediated mitotic chromatin assembly in Saccharomyces cerevisiae. Eukaryot Cell (2005) 0.82
The Saccharomyces cerevisiae anaphase-promoting complex interacts with multiple histone-modifying enzymes to regulate cell cycle progression. Eukaryot Cell (2010) 0.82
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Hum Genomics (2008) 0.80
Zinc Binding Properties of Engineered RING Finger Domain of Arkadia E3 Ubiquitin Ligase. Bioinorg Chem Appl (2010) 0.75
Expression analysis and association of RBBP6 with apoptosis in colon cancers. J Mol Histol (2016) 0.75
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 3.46
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res (2010) 2.87
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res (2011) 2.56
Discovering patterns to extract protein-protein interactions from full texts. Bioinformatics (2004) 2.42
Fractal analysis in the detection of colonic cancer images. IEEE Trans Inf Technol Biomed (2002) 2.18
A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: support vector machine classification of peptide MS/MS spectra and SEQUEST scores. J Proteome Res (2003) 2.16
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood (2009) 2.06
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther (2014) 2.03
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol (2007) 1.91
Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res (2005) 1.87
Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell (2005) 1.68
Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol (2006) 1.54
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum (2008) 1.44
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos (2011) 1.35
Activation of the PKB/AKT pathway by ICAM-2. Immunity (2002) 1.31
Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitin-conjugating enzyme. J Biol Chem (2007) 1.25
Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs (2004) 1.20
The poxvirus p28 virulence factor is an E3 ubiquitin ligase. J Biol Chem (2004) 1.14
i-SNAREs: inhibitory SNAREs that fine-tune the specificity of membrane fusion. J Cell Biol (2003) 1.14
Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINK beta. J Biol Chem (2004) 1.12
Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One (2011) 1.10
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09
The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells. Mol Immunol (2009) 1.07
Retrovirally delivered random cyclic Peptide libraries yield inhibitors of interleukin-4 signaling in human B cells. J Biol Chem (2002) 1.04
A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation. J Immunol (2005) 1.04
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther (2008) 1.03
Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway. J Med Chem (2010) 1.00
The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. Biochim Biophys Acta (2012) 1.00
AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes. PLoS One (2013) 0.94
Drug discovery in the ubiquitin regulatory pathway. Drug Discov Today (2003) 0.94
High-throughput screening for inhibitors of the e3 ubiquitin ligase APC. Methods Enzymol (2005) 0.92
JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol (2009) 0.88
Use of MEDUSA-based data analysis and capillary HPLC-ion-trap mass spectrometry to examine complex immunoaffinity extracts of RBAp48. J Proteome Res (2003) 0.87
A novel role for p21-activated protein kinase 2 in T cell activation. J Immunol (2004) 0.87
Multiple functional categories of proteins identified in an in vitro cellular ubiquitin affinity extract using shotgun peptide sequencing. J Proteome Res (2003) 0.87
The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol (2010) 0.86
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol (2010) 0.86
Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library. Chem Biol (2003) 0.85
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood (2011) 0.85
A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Chem Biol (2007) 0.84
Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J Med Chem (2012) 0.82
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. Am J Physiol Heart Circ Physiol (2014) 0.81
Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother (2008) 0.80
A homogeneous FRET assay system for multiubiquitin chain assembly and disassembly. Methods Enzymol (2005) 0.80
Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling. Eur J Med Chem (2012) 0.78
2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage. Eur J Pharmacol (2013) 0.78
Computational and experimental studies on human misshapen/NIK-related kinase MINK-1. Curr Med Chem (2004) 0.77
Granular cell tumor as an unusual cause of obstruction at the hepatic hilum: report of a case. Surg Today (2006) 0.77
Discovery of an Inhibitor of the Proteasome Subunit Rpn11. J Med Chem (2017) 0.76
Gas phase dimerization of neuropeptide head activator analogs useful for the noncovalent constraint of peptides. Biopolymers (2007) 0.76
Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways. BMC Res Notes (2014) 0.75
A modeling-derived hypothesis on chronicity in respiratory diseases: desensitized pathogen recognition secondary to hyperactive IRAK/TRAF6 signaling. PLoS One (2009) 0.75
R-253 disrupts microtubule networks in multiple tumor cell lines. Clin Cancer Res (2006) 0.75
Cellular interacting proteins of functional screen-derived antiproliferative and cytotoxic peptides discovered using shotgun peptide sequencing. Chem Biol (2003) 0.75
Correction to Discovery of an Inhibitor of the Proteasome Subunit Rpn11. J Med Chem (2017) 0.75
New fluorescent trans-dihydrofluoren-3-ones from aldol-Robinson annulation-regioselective addition involved one-pot reaction. Org Biomol Chem (2010) 0.75